(1 - 25 from 29
)
Q+A with Dr Marie Scully on Rare Disease Day | UCLH Biomedical...
www.uclhospitals.brc.nihr.ac.uk
The BRC spoke to Dr Marie Scully, whose research focus is thrombotic thrombocytopenic purpura (TTP), a rare blood disorder that causes blood clots to form in …
Investigator Profile: Marie Scully, M.D, Professor of ...
trialsitenews.com
Dr. Scully was the lead author of the HERCULES study. The objective of the Phase 3 study pre approval was to evaluate the long term-safety and efficacy of repeated use of caplacizumab (Cablivi® ) and to characterize long term impact of TTP. TTP is a rare, life threatening autoimmune blood disorder characterized by extensive clot formation […]
Caplacizumab induces response in acquired thrombotic Healio
www.healio.com
Marie Scully. ATLANTA — Caplacizumab reduced time to platelet count response and resulted in faster resolution of acquired thrombotic ...
First patient treated with IdeS in Phase II study in acquired...
www.globenewswire.com
The Clinical Investigator, Dr. Marie Scully, consultant haematologist at UCLH, is a leading expert in patient care and clinical research in TTP.
sorted by relevance / date